Ken Kato, MD, PhD: FDA Approval of Nivolumab for Esophageal Squamous Cell Carcinoma

The FDA recently approved nivolumab for patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior fluoropyrimidine- and platinum-based chemotherapy. Ken Kato, MD, PhD, lead author on the study the approval was based on, spoke to i3 Health about the challenges of treating this patient population, in addition to the significance of this approval. What are the most challenging aspects of treating patients with advanced ESCC refra...
Continue reading

Eradicating H. Pylori Reduces Gastric Cancer Risk

Being infected with Helicobacter pylori (H. pylori), a bacterium that grows in the stomach, and having a family history of gastric cancer are the two main risk factors for developing gastric cancer. Results from a recent study revealed that treatment to eradicate H. pylori can help reduce gastric cancer risk in those who have the bacterium and a family history of the disease. For the single-center, double-blind, placebo-controlled study, results of which are published in The New England Journal ...
Continue reading

Eribulin Is Effective in Metastatic Breast Cancer

For many patients with metastatic breast cancer, a resistance to hormone therapy develops, and cumulative toxicity, comorbidities, performance status, and prior adjuvant therapy influence the next step for treatment. Due to all of these factors, finding an effective, well-tolerated treatment can be difficult. However, results from a phase 3 clinical trial, published in the European Journal of Cancer, reveal that scientists are a step closer to this goal: eribulin (HalavenĀ®, Eisai Inc.) monothera...
Continue reading

Copyright Ā© 2020 i3 Health. All rights reserved.